News Snapshot:
“Every quarter they’ve reported since the IPO in our view [shows] they have strong operational momentum,” said Mr Osmani. “While we were initially thinking its path to profitability will be somewhere around six years down the line, we actually think it could potentially become profitable within three years.” The fund manager said Martin Currie’s global fund also owns $US32.4 billion ($50.9 billion) Nasdaq-listed genetic sequencing biotech Illumina. “We’re looking at revenue growth for Illumina of 17 per cent annualised over the next five years. So attractive growth, rapidly improving ROIC in a space with very positive structural growth prospects,” Mr...
